Return to home page
Searching: Muskingum library catalog
Some OPAL libraries remain closed or are operating at reduced service levels. Materials from those libraries may not be requestable; requested items may take longer to arrive. Note that pickup procedures may differ between libraries. Please contact your library for new procedures, specific requests, or other assistance.
  Previous Record Previous Item Next Item Next Record
  Reviews, Summaries, etc...
EBOOK
Title Gene therapy for cancer / edited by Kelly K. Hunt, Stephan A. Vorburger, Stephen G. Swisher.
Imprint Totowa, N.J. : Humana Press, 2007.

LOCATION CALL # STATUS MESSAGE
 OHIOLINK SPRINGER EBOOKS    ONLINE  
View online
LOCATION CALL # STATUS MESSAGE
 OHIOLINK SPRINGER EBOOKS    ONLINE  
View online
Series Cancer drug discovery and development
Cancer drug discovery and development.
Subject Cancer -- Gene therapy.
Neoplasms -- genetics.
Neoplasms -- therapy.
Genetic Therapy -- methods.
Alt Name Hunt, Kelly K.
Vorburger, Stephan A.
Swisher, Stephen G.
Description 1 online resource (xi, 469 pages) : illustrations (some color).
Bibliography Note Includes bibliographical references and index.
Contents Adenovector-mediated cancer gene therapy / Bingliang Fang and Jack A. Roth -- Efficacy, toxicity, and immunogenicity of adenoviral vectors / Dmitry M. Shayakhmetov -- Lentiviral and retroviral vector systems / Renata Stripecke and Noriyuki Kasahara -- Vaccinia and pox-virus / Sricharan Chalikonda and David L. Bartlett -- Herpes simplex virus as a therapy for cancer / Ian J. Mohr -- Alphavirus vectors for gene therapy applications / Kenneth Lundstrom -- Vesicular stomatitis virus and RNA viruses as gene therapy vectors / Glen N. Barber -- Parvovirus vectors / Selvarangan Ponnazhagan -- Nonviral vector systems / Pui-yan Lee and Leaf Huang -- Oncogenes, tumor suppressor genes, and apoptosis-inducing genes utilized in cancer gene therapy / Lidong Zhang and Bingliang Fang -- Gene silencing therapy against cancer / Chao-Zhong Song -- Tumor targeting-retargeted adenovirus / Masato Yamamoto and David T. Curiel -- Oncolytic herpes simplex for gene therapy in preclinical and clinical trials / Richard H. Pin [and others] -- Cytokine gene therapy for genitourinary cancer / Terry L. Timme [and others] -- Combination of gene therapy with radiation / Anupama Munshi and Raymond E. Meyn.
Gene transfer for chemoprotection and enrichment of hematopoietic stem cells / Justin C. Roth and Stanton L. Gerson -- Nonviral genetic vaccines for cancer / Steven R. Little, Daniel G. Anderson, and Robert Langer -- Gene therapy targeted at angiogenesis and lymphangiogenesis for cancer treatment / Anita T. Tandle and Steven K. Libutti -- Tumor-specific replicating adenoviruses : delta 24 for human gliomas / Giacomo G. Vecil, Juan Fueyo, and Frederick F. Lang -- Problems, side effects, and disappointments in clinical cancer gene therapy / Ta-Chiang Liu and David H. Kirn -- Trials and tribulations in developing clinical trials of gene therapy : E1A for breast or ovarian cancer / Naoto T. Ueno [and others] -- Phase I clinical experience with intravenous administration of PV701, an oncolytic virus / Andrew L. Pecora and Robert M. Lorence -- MDA-7/IL-24 as a multi-modality therapy for cancer / Sunil Chada [and others] -- Development of therapeutic genes for breast cancer treatment / Mien-Chie Hung and Duen-Hwa Yan -- Steps in a translational cancer gene therapy trial / Urs W. von Holzen and Stephen G. Swisher.
Summary The possibility of treating cancer, a disease defined by genetic defects, by introducing genes targeting these very alterations has led to an immense interest in gene therapy for cancer. Although incremental successes have been realized, enthusiasm for gene therapy has declined due to an increasing number of obstacles. These obstacles include vector systems that do not reach systemic metastases, therapeutic genes with redundant mec- nisms allowing for cellular resistance, and toxicities in clinical trials leading to premature closure of these studies. Different tactics to overcome or circumvent these obstacles have catalyzed the development of a wide range of gene therapy approaches. Thus far, almost two-thirds of gene therapy trials have focused on cancer. This reflects the concept that gene therapy approaches for the treatment of cancer do not necessarily require long-term expression of the gene as is necessary for the treatment of primary genetic defects like hemophilia or juvenile diabetes. Unlike the treatment of genetic defects, where expr- sion of the corrected gene needs to be strong, permanent and, sometimes regulated, tactics to treat tumors can be based on temporary and locally limited effects. In addition, cancer cells have different properties than normal cells and this allows for targeting gene therapy to specific cells, a major advantage over current antitumor therapies, which are also toxic to normal cells and tissues.
Note English.
ISBN 1588294722 (alk. paper)
9781588294722 (alk. paper)
9781597452229 (electronic bk.)
159745222X (electronic bk.)
1280971800
9781280971808
ISBN/ISSN 9786610971800
10.1007/978-1-59745-222-9
OCLC # 173642865
Link Springer e-books
Additional Format Print version: Gene therapy for cancer. Totowa, N.J. : Humana Press, 2007 1588294722 9781588294722 (DLC) 2006012653 (OCoLC)67282612


If you experience difficulty accessing or navigating this content, please contact the OPAL Support Team